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Objectives The purpose of this study was to assess whether changes of major atrial fibrillation (AF) risk factors and/or intercur-
rent cardiovascular events could explain the relationship between type 2 diabetes mellitus (T2D) and incident AF.
Background Previous studies found an increased risk of incident AF among individuals with T2D, but few, if any, of these
studies took into account changes of AF risk factors over time.
Methods A total of 34,720 female health professionals who participated in the Women’s Health Study, and who were free
of cardiovascular disease and AF at baseline were followed for a median of 16.4 years. Cox proportional-hazards
models were constructed to assess the relationship between T2D and incident AF, using either information at
baseline or time-varying covariates for both T2D and potential confounders.
Results At baseline, 937 (2.7 %) women had T2D. Compared with women without T2D, women with T2D had an age-
adjusted hazard ratio (HR) for new-onset AF of 1.95 (95% confidence interval [CI]: 1.49 to 2.56; p  0.0001). In
multivariable analyses adjusting for baseline confounders, this HR was substantially attenuated, but baseline
T2D remained a significant predictor of incident AF (HR: 1.37, 95% CI: 1.03 to 1.83; p  0.03). In time-updated
models that adjusted for changes in AF risk factors and intercurrent cardiovascular events, the HR for T2D was
attenuated further and became nonsignificant (HR: 1.14; 95% CI: 0.93 to 1.40; p  0.20).
Conclusions Although this study confirms a significant relationship between baseline T2D and incident AF, our data suggest
that the increased risk associated with T2D is mainly mediated by changes of other AF risk factors. (J Am Coll
Cardiol 2012;60:1421–8) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.06.030d
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AAtrial fibrillation (AF) is the most common cardiac arrhyth-
mia in the general population (1), and its prevalence is
projected to increase substantially over the next decades (2).
ndividuals with AF have an increased risk of major com-
lications, including death, stroke, and congestive heart
ailure, even after adjustment for relevant comorbidities
3–8), such that defining and treating risk factors for AF
ccurrence is a major public health priority.
Several prospective studies evaluated the relationship
etween type 2 diabetes (T2D) and incident AF, and
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nalysis found a modest, but statistically significant in-
reased risk of new-onset AF among individuals with T2D
summary relative risk: 1.34 [95% confidence interval (CI):
.07 to 1.68]) (16). However, significant between-study
eterogeneity was observed, part of which might be ex-
lained by the fact that studies with more extensive multi-
ariable adjustment were associated with smaller relative risk
stimates than studies with less extensive adjustments (p for
eterogeneity  0.053) (16).
Given the close relationship of T2D with obesity and
ypertension (17), which are 2 of the strongest risk factors for
ew-onset AF (15,18–20), adequate adjustment in the evalu-
tion of the association between T2D and AF is a relevant
ssue. The observed association between baseline T2D and AF
ay be due to differential changes of these risk factors in
iabetic compared with nondiabetic subjects, because of the
ncreased risk of weight gain and hypertension among patients
ith established T2D (21–23).
Few if any studies on the association between T2D and
F have taken into account changes of risk factors over time
fter the development of T2D (9–15,24,25). Because detailed
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is important to optimize mea-
sures for AF disease prevention
in the population, the primary
aim of this study was to prospec-
tively examine whether changes
of major AF risk factors over
time and intercurrent cardiovas-
cular events may explain the pre-
viously observed association be-
tween T2D and AF.
Methods
Study participants. All study subjects participated in the WHS
(Women’s Health Study), a completed randomized trial
among 39,876 women evaluating benefits and risks of
low-dose aspirin (100 mg every other day) and vitamin E
(600 IU every other day) in the primary prevention of
cardiovascular disease and cancer, using a randomized,
double-blind, placebo-controlled study design. Details
about the conduct of the study have been previously pub-
lished (26–28).
Participants were female health professionals in the
United States, age 45 years and free of cardiovascular
disease, cancer, or other major illnesses at study entry.
Randomized treatment ended on March 31, 2004, and all
women were invited to participate in continued observa-
tional follow-up, which for the present analysis was trun-
cated on March 2, 2011. Of the original cohort, we excluded
897 women (2.2%) with a history of AF at baseline and 54
(0.1%) women with a confirmed cardiovascular event
(stroke, heart failure, or myocardial infarction) before study
entry. In addition, 4,205 (10.5%) women did not participate
in the observational follow-up, leaving 34,720 participants
for the present analysis. The study was approved by the
institutional review board of Brigham and Women’s Hos-
pital, Boston, and was monitored by an external data and
safety monitoring board.
Study variables. Mailed questionnaires were used to collect
information on baseline characteristics. To obtain informa-
tion on study outcomes, changes in covariates, and other
information, follow-up questionnaires were sent to all par-
ticipants every 6 months during the first year and every 12
months thereafter. Covariates of interest included age,
hypertension, body mass index (BMI) (weight in kilograms
divided by height in meters squared), hypercholesterolemia,
physical exercise, self-reported race/ethnicity, highest edu-
cation level, smoking, and alcohol consumption.
Ascertainment of incident type 2 diabetes. Details re-
garding the ascertainment of incident T2D in the WHS
have been previously reported (29). Briefly, participants
were asked annually whether and when they had been
diagnosed with diabetes since baseline. Confirmation of
T2D was conducted using American Diabetes Association
Abbreviations
and Acronyms
AF  atrial fibrillation
BMI  body mass index
CI  confidence interval
HbA1c  glycosylated
hemoglobin A1c
HR  hazard ratio
T2D  type 2 diabetes
mellitusdiagnostic criteria (30). Self-reported cases were investi-gated by either telephone interview conducted by a physi-
cian or a self-administered supplemental questionnaire that
inquired about symptoms, diagnostic testing, and use of
diabetes medications. In a validation study (31), the self-
administered questionnaire proved highly accurate for con-
firmation of clinical diabetes compared with medical record
review. Thus, since 1999, confirmation of T2D has relied
upon supplemental questionnaires. Overall, in 95% of all
post-randomization self-reported diabetes, sufficient infor-
mation for confirmation or disconfirmation of the endpoint
was obtained. In addition, among women with available
baseline levels of hemoglobin A1c (HbA1c) and without a
baseline diagnosis of T2D, the prevalence of HbA1c 6.5%
was only 0.5%. Only confirmed cases of incident T2D were
included in this study.
Ascertainment of incident atrial fibrillation. Details
about AF endpoint confirmation have been previously
published (18,32). Briefly, participating women were asked
about incident AF diagnoses at baseline, after 48 months,
and annually thereafter. Women who participated in the
continued observational follow-up who indicated the occur-
rence of an incident AF event on 1 yearly questionnaires
were sent a supplemental questionnaire to collect additional
information and to obtain written informed consent for
medical record review. For all deceased participants who
reported AF during the trial and extended follow-up period,
family members were contacted to obtain consent and
additional relevant information. An endpoint committee of
cardiovascular physicians reviewed medical records for reported
events according to predefined criteria. An AF event was
confirmed if there was electrocardiographic evidence of AF or
if a medical report clearly indicated a personal history of AF.
Only confirmed AF events were included in the present study.
Ascertainment of incident cardiovascular events. Collec-
tion of cardiovascular endpoints occurred through question-
naires, letters, and phone calls, as described previously
(8,26). A blinded endpoint committee of physicians adju-
dicated all events according to predefined criteria (26).
Information on stroke and myocardial infarction was col-
lected from the beginning of the study. Incident diagnoses
of congestive heart failure were reported for the first time at
the 48-month questionnaire. Heart failure was confirmed if
participants met either the Framingham Heart Study (33)
or the Cardiovascular Health Study (34) criteria for the
presence of heart failure, and both definite and probable
cases were included in the analysis.
Measurement of HbA1c levels. Blood samples at study
ntry were obtained from 28,345 women. Levels of HbA1c
were estimated using the Tina-Quant turbidimetric inhibi-
tion immunoassay on a Hitachi 911 (Roche Diagnostics,
Indianapolis, Indiana) autoanalyzer using packed red blood
cells (35). The assay is specific for HbA1c, standardized
against the approved International Federation of Clinical
Chemists reference method, and traceable to the Diabetes
Control and Complications Trial by use of a conversion
factor. Values of HbA1c presented in this study are Diabetes
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variation for HbA1c computed from blinded simultaneously
analyzed quality controls was 7.2%.
Statistical analysis. Wilcoxon rank-sum tests for continu-
ous variables and chi-square tests for categorical variables
were used to compare baseline characteristics of women
with and without T2D at study entry. Person-years of
follow-up were calculated from the date of return of the
baseline questionnaire to the first occurrence of new-onset
AF, death, loss to follow-up, or March 2, 2011.
Cox proportional hazards models were constructed to
calculate hazard ratios (HRs) and 95% CIs for incident AF
and to adjust for potential confounders. Age-adjusted mod-
els were further adjusted for adult height, smoking, exercise,
alcohol consumption, education, race/ethnicity, and hyper-
cholesterolemia. Because of the close relationship among
BMI, hypertension, and T2D (17), these variables were
added in separate steps to the multivariable models.
To evaluate the influence of covariate changes over time,
we then constructed multivariable Cox models where T2D
and all other covariates were updated during follow-up
whenever follow-up values were available. We adjusted
these multivariable models according to the same previously
described pre-specified order, but added a final step where we
additionally adjusted for intercurrent cardiovascular events,
defined as stroke, myocardial infarction, or congestive heart
failure. Finally, to assess the potential bidirectional nature of
Baseline Characteristics According to the PreseTable 1 Baseline Characteristics According
Characteristic
(N  34,720)
No Baselin
(n  33,
Age, yrs 52.8 (48
Body mass index, kg/m2 24.9 (22
Adult height, cm 165 (16
History of hypertension 8,586 (25
History of hypercholesterolemia 10,041 (29
Smoking
Current 4,179 (12
Past 12,139 (35
Never 17,439 (51
Alcohol consumption
Rarely/never 14,706 (43
1–3 drinks/month 4,463 (13
3–6 drinks/week 11,052 (32
1 drinks/day 3,552 (10
Highest education level
Less than a bachelor’s degree 18,438 (54
Bachelor’s degree 7,900 (23
Master’s degree or doctorate 6,876 (20
Exercise, times/wk
Rarely/never 12,646 (37
 1 6,693 (19
1–3 10,734 (31
 4 3,695 (10
Values are median (interquartile ranges) or counts (percentages). Nu
because of missing data. *Based on Kruskal-Wallis tests for continuous varia
T2D  type 2 diabetes.the relationship between T2D, hypertension, and BMI, we
constructed a similar series of multivariable Cox models for
BMI and hypertension, where T2D was added as a covariate in
a separate step.
To gain further insights on the role of glucose homeo-
stasis in AF development, we assessed the relationship
between approximate quartiles of HbA1c levels and incident
AF in age- and multivariable-adjusted Cox models among
women with available HbA1c levels at baseline. Tests for
inear trend were performed by assigning all women the
uartile-specific median HbA1c value. To evaluate the effect
f elevated HbA1c values, we repeated the same analyses
after dichotomizing HbA1c levels at the 95th percentile.
Finally, we also specifically assessed the association between
HbA1c and incident AF among women with baseline T2D.
Categorical variables were entered into the Cox models
sing binary indicator variables. Multiplicative interaction
erms between T2D and several baseline characteristics were
valuated in the fully adjusted baseline models using likeli-
ood ratio tests. All analyses were performed using SAS
ersion 9.2 (SAS Institute Inc, Cary, North Carolina). A
-tailed p value 0.05 was pre-specified to indicate statis-
ical significance.
esults
aseline characteristics. Baseline characteristics stratified
y the presence or absence of T2D are presented in Table 1.
or Absence of T2De Presence or Absence of T2D
Baseline T2D
(n  937) p Value*
7) 55.5 (50.0–62.1) 0.0001
3) 30.0 (26.3–34.6) 0.0001
) 165 (160–170) 0.23
589 (62.9%) 0.0001
443 (47.3%) 0.0001
127 (13.6%) 0.49
343 (36.6%)
467 (49.8%)
655 (69.9%) 0.0001
122 (13.0%)
124 (13.2%)
36 (3.8%)
599 (63.9%) 0.0001
190 (20.3%)
127 (13.6%)
446 (47.6%) 0.0001
187 (20.0%)
229 (24.4%)
75 (8.0%)
f observations across categories may not sum to the given numbernceto th
e T2D
783)
.9–58.
.5–28.
0–168
.4%)
.7%)
.4%)
.9%)
.6%)
.5%)
.2%)
.7%)
.5%)
.6%)
.4%)
.4%)
.4%)
.8%)
.8%)
.9%)
mber o
bles and chi-square tests for categorical variables.
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Diabetes and Incident AF in Women October 9, 2012:1421–8At study entry, 937 women (2.7 %) had T2D. Women with
T2D were significantly older, had a higher BMI, a higher
prevalence of hypertension, a lower educational level, and
exercised less frequently compared with women without
T2D (all p  0.0001).
Baseline T2D and new-onset AF. During a median
follow-up of 16.4 years (interquartile range: 15.6 to 16.8
years), 1,079 (3.1%) women developed incident AF. The
age-adjusted incidence rate for new-onset AF was 3.97 and
1.99 per 1,000 person-years of follow-up among women
with and without baseline T2D, respectively (Table 2, upper
section). Accordingly, in Cox proportional-hazards models,
the age-adjusted HR for women with baseline T2D was
1.95 (95% CI: 1.49 to 2.56; p  0.0001). Multivariable
adjustment for established cardiovascular risk factors, but
not BMI and hypertension, had little effect on this risk
estimate (HR: 1.87: 95% CI: 1.41 to 2.47; p 0.0001).
Although additional adjustment for hypertension and BMI
substantially attenuated this relationship, a significant effect
of baseline T2D persisted in the fully adjusted model (HR:
1.37; 95% CI; 1.03 to 1.83; p  0.03). BMI and hyperten-
sion were strong and significant risk factors of incident AF
in all models, and the effect of adding T2D to these models
was small (Online Tables 1 and 2).
Models with time-updated covariates. Among women
without T2D at baseline, 2,730 (7.9%) developed new-onset
T2D during follow-up. Sixty-eight (2.5 %) of these women
had a subsequent diagnosis of new-onset AF, which corre-
Risk of Incident AF According to the Presence oTable 2 Risk of Incident AF According to th
Models With Basel
No T2D at B
(n  33,
No. of events/person-years 1,023/528
Age-adjusted incidence rate 1.99
Age-adjusted model Refere
Multivariable-adjusted model*† Refere
Hypertension† Refere
BMI‡ Refere
Hypertension and BMI‡ Refere
Models Using Tim
Never
(n  31
No. of events/person-years 955/50
Age-adjusted incidence rate 1.9
Age-adjusted model Refe
Multivariable-adjusted model*† Refe
Hypertension† Refe
BMI‡ Refe
Hypertension and BMI‡ Refe
Hypertension, BMI, and intercurrent
cardiovascular events‡
Refe
Values are counts, rates per 1,000 person-years of follow-up, or hazard
exercise, alcohol consumption, education, race/ethnicity, hypercholes
33,757 women because of missing data. ‡hese models were based on 1,02
BMI  body mass index; other abbreviations as in Table 1.sponded to an age-adjusted incidence rate of 3.62 events per
1,000 person-years among women with new-onset T2D, as
shown in Table 2. In multivariable models that did not
adjust for hypertension and BMI, T2D was significantly
associated with incident AF (HR: 1.58; 95% CI: 1.30 to
1.93; p  0.0001) (Table 2, lower section). When BMI and
hypertension were added to this model, the association
between T2D and new-onset AF was weakened and no
longer statistically significant (HR: 1.19; 95% CI: 0.97 to
1.45; p  0.10).
Among women with T2D, significantly more AF events
were preceded by a cardiovascular event compared with
women without T2D (16 of 124 [12.9%] vs. 39 of 955
[4.1%]; p  0.001). After additional adjustment for these
intercurrent events, the multivariable adjusted relative risk
was further attenuated (HR: 1.14; 95% CI: 0.93 to 1.40; p 
0.20), as shown in Table 2. Again, BMI and hypertension
were strongly associated with incident AF in all models and
adding T2D only minimally altered these results (Online
Tables 1 and 2).
Subgroup analyses. Subgroup analyses are displayed in
Table 3. The relationship between baseline T2D and
incident AF was stronger among women age 65 years
(HR: 1.54; 95% CI: 1.13 to 2.11) than among women age
65 years (HR: 0.85; 95% CI: 0.42 to 1.74) (p for
interaction  0.01). Again, in women age 65 years, the
effect of T2D on incident AF was attenuated in fully
adjusted time-updated Cox models (HR: 1.24; 95% CI 0.99
sence of T2Dsence or Absence of T2D
aracteristics Only
e T2D at Baseline
(n  937) p Value
56/13,192 —
3.97 —
1.95 (1.49–2.56) 0.0001
1.87 (1.41–2.47) 0.0001
1.62 (1.22–2.14) 0.0008
1.47 (1.11–1.96) 0.008
1.37 (1.03–1.83) 0.03
ated Covariates
Baseline or Incident T2D
(n  3,667) p Value
124/33,448 —
Baseline T2D: 3.97
Incident T2D: 3.62
1.63 (1.35–1.96) 0.0001
1.58 (1.30–1.93) 0.0001
1.42 (1.16–1.73) 0.0005
1.24 (1.01–1.53) 0.04
1.19 (0.97–1.45) 0.10
1.14 (0.93–1.40) 0.20
95% confidence intervals) as appropriate. *Adjusted for age, smoking,
ia, and adult height. †These models were based on 1,040 events inr Abe Pre
ine Ch
aselin
783)
,106
nt
nt
nt
nt
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e–Upd
T2D
,053)
7,851
8
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rent
rent
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rent
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ratios (
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October 9, 2012:1421–8 Diabetes and Incident AF in Womento 1.55). Consistent findings with nonsignificant interaction
tests were obtained for all other subgroups assessed.
HbA1c levels and new-onset AF. Among 28,345 women
ith available blood samples at baseline, 25,290 were
ligible for the present analysis, of whom 24,890 (98%)
ad a valid HbA1c measurement. In this subcohort, 835
confirmed incident AF events occurred. HbA1c at study
entry was not significantly associated with incident AF.
The age- and multivariable-adjusted models for quartiles
of HbA1c are shown in Table 4, and the p values for
linear trend across quartiles were nonsignificant. When
extreme levels above the 95th percentile (i.e., 5.6%)
were examined, the age-adjusted association was signifi-
T2D and Risk of Incident AF, Stratified by SelecTable 3 T2D and Risk of Incident AF, Strati
Characteristic
No Baseline T2
(n  33,783
Age  65 yrs
Yes (n  3,430)
Events/participants 250/3,294
HR (95% CI) 1 (Reference
No (n  31,290)
Events/participants 773/30,489
HR (95% CI) 1 (Reference
Body mass index
25 kg/m2 (n  17,720)
Events/participants 431/17,546
HR (95% CI) 1 (Reference
25–30 kg/m2 (n  10,707)
Events/participants 331/10,418
HR (95% CI) 1 (Reference
30 kg/m2 (n  6,260)
Events/participants 260/5,791
HR (95% CI) 1 (Reference
Hypertension
Yes (n  9,175)
Events/participants 430/8,586
HR (95% CI) 1 (Reference
No (n  25,545)
Events/participants 593/25,197
HR (95% CI) 1 (Reference
Hypercholesterolemia
Yes (n  10,484)
Events/participants 359/10,041
HR (95% CI) 1 (Reference
No (n  24,236)
Events/participants 664/23,742
HR (95% CI) 1 (Reference
Current smoking
Yes (n  4,306)
Events/participants 92/4,179
HR (95% CI) 1 (Reference
No (n  30,388)
Events/participants 929/29,578
HR (95% CI) 1 (Reference
All hazard ratios were adjusted for age, smoking, exercise, alcohol c
body mass index, and adult height. *p Value for interaction based on
AF  atrial fibrillation; CI  confidence interval; HR  hazard ratio;cant (HR: 1.53; 95% CI: 1.20 to 1.96), but was highly sattenuated and became nonsignificant after multivariable
adjustment (HR: 1.13; 95% CI: 0.87 to 1.48). Finally,
stratifying women by the presence or absence of T2D at
baseline provided similar results. Among the 647 women
with T2D at baseline, the multivariable HR for each 1%
increase in HbA1c was 1.09 (95% CI: 0.93 to 1.27). The
orresponding HR among the nondiabetic women was
.87 (95% CI: 0.71 to 1.07).
iscussion
n this large, prospective cohort of initially healthy middle-
ged women, baseline T2D was a modest, but statistically
aseline Characteristicsy Selected Baseline Characteristics
Baseline T2D
(n  937) p Value*
0.01
8/136
0.85 (0.42–1.74)
48/801
1.54 (1.13–2.11)
0.10
3/174
0.53 (0.17–1.66)
16/289
1.19 (0.68–2.09)
37/469
1.73 (1.21–2.48)
0.70
44/589
1.43 (1.03–2.00)
12/348
1.22 (0.69–2.17)
0.82
27/443
1.37 (0.91–2.07)
29/494
1.35 (0.91–2.02)
0.98
5/127
1.48 (0.57–3.84)
51/810
1.35 (1.00–1.83)
tion, education, race/ethnicity, hypercholesterolemia, hypertension,
hood ratio test with and without interaction terms in the models.
bbreviations as in Table 1.ted Bfied b
D
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)
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Diabetes and Incident AF in Women October 9, 2012:1421–8adjustment. Similar to previous studies on this issue, we
found that the risk of incident AF among women with T2D
was increased approximately 2-fold after adjustment for age,
and that this risk was attenuated to about 1.4 after more
extensive multivariable adjustment for baseline risk factors
(9,12,14,16). The present study added to this literature by
showing that much of the remaining association between
T2D and AF in these previous studies could be accounted
for by the development over time of hypertension, obesity,
and cardiovascular disease. We also found that the effect of
T2D on incident AF was stronger in younger women (p for
interaction 0.01). The reason for this finding was unclear,
but it might suggest that environmental factors leading to
hypertension and obesity are less important in younger
individuals with T2D.
Our data suggested that the adiposity and hypertension
associated with T2D were more important for AF develop-
ment than glucose homeostasis, a concept that was sup-
ported by at least 2 lines of evidence. First, we found no
relationship between HbA1c levels and incident AF in
women with and without established T2D who had avail-
able blood samples. However, a recent study found that
elevated HbA1c levels were associated with an increased risk
of AF occurrence in the subgroup of participants with
established T2D (25). The reasons for these differential
findings were unclear, but might be related to the fact that
a more severe endpoint (AF hospitalizations) was assessed
in the earlier study or that a different sample population was
evaluated (community-based cohort vs. initially healthy
female health professionals). Alternatively, the relatively
small subgroup of women with T2D and available HbA1c
levels in our study might have limited our power to detect
such an association. The upper limit of the 95% CI in our
analysis suggested that our study could not exclude an
increased risk of incident AF up to 27% for each 1% increase
in HbA1c among women with T2D, an order of magnitude
well in line with the risk estimate of the previous analysis
(25). In contrast, the tight 95% CIs (HR: 0.87; 95% CI:
0.71 to 1.07) for HbA1c in the much larger group of
ondiabetic women did confidently rule out even a modest
ncrease in risk. Second, recent data from the Framingham
HbA1c and Risk of Incident AF Among 24,890 Women With AvailabTable 4 HbA1c and Risk of Incident AF Among 24,890 Women
Characteristics 1 2
(N  24,890) <4.84% 4.84%–5.00%
No. of events/participants 170/6,275 181/6,149
Age-adjusted incidence rate 2.05 1.99
Age-adjusted model Referent 0.97 (0.79–1.20)
Multivariable-adjusted model†‡ Referent 0.99 (0.80–1.22)
Hypertension and BMI§ Referent 0.95 (0.76–1.17)
Data are counts, rates per 1,000 person-years of follow-up, or hazard ratios (95% CIs) as appropri
ge, smoking, exercise, alcohol consumption, education, race/ethnicity, hypercholesterolemia, an
These models were based on 794 events in 23,921 women because of missing data.
HbA1c  glycosylated hemoglobin; other abbreviations as in Tables 2 and 3.eart Study investigators showed that insulin resistance did mot independently increase the risk of incident AF, with a
ultivariable adjusted HR for new-onset AF associated
ith insulin resistance of 1.03 (95% CI: 0.72 to 1.46) (36).
In contrast to these negative findings, the strong and
ndependent relationships of obesity and elevated blood
ressure, 2 important T2D-related comorbidities (17), with
F development were demonstrated in several independent
tudies (18–20,37). These relationships persisted in models
hat took into account changes of covariates over time
18,19), and were only minimally affected in the present
tudy by adding T2D to the models. Population attributable
isks around 20% for overweight and obesity (19,37), and up
o 25% for elevated blood pressure (37), further highlighted
he importance of overweight and elevated blood pressure as
F risk factors. Because patients with T2D are more likely
o have additional weight gain and increases in blood
ressure, taking into account changes in these risk factors
ver time was important to isolate any residual association
ttributable to diabetes independent of these factors. Inter-
stingly, obesity, hypertension, T2D, and AF were all
trongly related to blood levels of inflammatory biomarkers
n earlier studies, such that inflammation might be an important
athophysiological link between these variables (19,38,39).
ith regard to clinical implications, our data suggest that
revention of AF among individuals with T2D should focus
n the strict control of body weight and blood pressure (40).
The occurrence of cardiovascular events is a strong risk
actor for incident AF (14,37) and an important determi-
ant of an adverse outcome in AF patients (8). Because
atients with T2D have an increased risk of developing
ardiovascular events (41), we hypothesized that intercur-
ent cardiovascular events could also mediate AF risk in
hese patients. However, although significantly more AF
vents were preceded by a cardiovascular event in women
ith T2D, the majority of AF events occurred indepen-
ently of an overt cardiovascular event also among individ-
als with T2D. Accordingly, our multivariable models
uggested that once changes in blood pressure and body
eight were taken into account, only a small part of the
elationship between baseline T2D and new-onset AF
A1c LevelsAvailable HbA1c Levels
HbA1c Quartiles
3 4
p Value for Trend*5.00%–5.19% >5.19%
235/6,293 249/6,173 —
2.33 2.37 —
1.12 (0.92–1.37) 1.12 (0.91–1.37) 0.16
1.07 (0.87–1.31) 1.11 (0.90–1.36) 0.22
0.97 (0.79–1.19) 0.90 (0.73–1.11) 0.35
value for trend across quartiles of HbA1c using quartile-specific medians of HbA1c. †Adjusted for
t height. ‡These models were based on 806 events in 24,194 women because of missing data.le HbWith
ate. *P
d adulight be mediated by nonfatal cardiovascular events.
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October 9, 2012:1421–8 Diabetes and Incident AF in WomenStrengths and limitations. Strengths of the present study
ncluded the prospective design, the large sample size, and
omplete long-term follow-up with a large number of events
onfirmed by medical record review and regular covariate
pdate. Potential study limitations should also be consid-
red. First, most participants of the present study were
aucasian women, and generalization of our findings to
ifferent populations should be done cautiously. Second,
ome AF cases might have been undetected because of
symptomatic AF episodes. The only way to obtain a true
icture of the AF prevalence would be by long-term
ontinuous Holter monitoring, which unfortunately is not
easible in large long-term cohort studies of this type. Third,
efining the onset of the initial AF episode might be
hallenging. Fourth, underdiagnosis of T2D might have
ccurred, given the lack of systematic T2D screening. Fifth,
ubclinical hyperthyroidism was repeatedly associated with
n increased risk of AF and might also be related to T2D
42,43). Because information on thyroid function was not
vailable in this study, we were unable to assess its role in
he relationship between T2D and incident AF.
onclusions
n this large cohort of initially healthy women, T2D at study
ntry was associated with a modest increase in risk of
ncident AF. Most of this increased risk seemed to be
ediated through excess weight gain and a higher preva-
ence of hypertension among individuals with T2D, such
hat the impact of diabetes beyond these risk factors was less
mportant. Therefore, strategies for AF prevention in dia-
etic patients should focus on the control of T2D-associated
omorbidities, in particular weight maintenance and blood
ressure control.
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